Travere Therapeutics' Path to Profitability: Analyst Expectations and Growth Rate

Travere Therapeutics is a biopharmaceutical company expected to reach breakeven in 2025, according to 14 American Biotechs analysts. The company is projected to post a final loss in 2025 and a profit of $25m in 2026. Analysts expect an average annual growth rate of 68%, which may be too aggressive if the company becomes profitable later than expected. Travere Therapeutics has a debt-to-equity ratio of over 2x, increasing the risk of investing in the loss-making company.

Citi has raised the price target for Travere Therapeutics Inc. (NASDAQ: TVTX) to $34 from $32, maintaining a Buy rating on the shares. The firm sees significant potential upside for the shares with two near-term FDA action dates for Travere [1]. The company reported its Q2 2025 financial results, showing a revenue of $114.4 million, up from $54.1 million in Q2 2024, driven by a 165% year-over-year growth in US net product sales of FILSPARI, which reached $71.9 million [1].

Analysts expect Travere Therapeutics to reach breakeven in 2025 and post a profit of $25 million in 2026, with an average annual growth rate of 68% [2]. However, the company's debt-to-equity ratio of over 2x increases the risk of investing in the loss-making company.

The FDA accepted Travere's supplemental new drug application (sNDA) for FILSPARI for the treatment of focal segmental glomerulosclerosis (FSGS), setting a PDUFA target action date of January 13, 2026. If approved, FILSPARI would be the first FDA-approved treatment for FSGS [1]. The company also expects a PDUFA action date of August 28 this year for its sNDA to modify the FILSPARI REMS program, which would remove the embryo-fetal toxicity monitoring requirement and reduce the frequency of liver monitoring [1].

References:
[1] https://finance.yahoo.com/news/citi-lifts-travere-therapeutics-tvtx-034110373.html
[2] https://www.marketwatch.com/investing/stock/tvtx